Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHsMichael Dougan, Stephanie K. Dougan, Patrick T. Bruck et al.|Cancer Immunology Research|2018Cited by 82
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancerAna C. Garrido-Castro, Sara M. Tolaney, Noah Graham et al.|Journal for ImmunoTherapy of Cancer|2025Cited by 15